APOE e2/e2
The APOE e2/e2 genotype is associated with increased triglycerides and reduced total cholesterol levels in the blood. Usually, people with this genotype have a decreased risk for cardiovascular disease (strokes, heart attacks) and respond well to treatment with a class of lipid-lowering drugs called statins.
Conversely, in people with the e2/e2 genotype, extremely low-fat diets can increase small dense LDL levels (bad cholesterol levels), and therefore these individuals should have a moderate fat restriction.
- Alzheimer’s Disease Risk:
The APOE e2/e2 genotype may provide some protection against Alzheimer’s disease. However, this does not necessarily mean that you won’t develop the disease in the future.
APOE e2/e3
The e2/e3 genotype is associated with increased triglycerides and reduced total cholesterol levels in the blood. Usually, people with this genotype have a decreased risk for cardiovascular disease (strokes, heart attacks) and respond well to treatment with a class of lipid-lowering drugs called statins.
Conversely, in people with the e2/e3 genotype, extremely low-fat diets can increase small dense LDL levels (bad cholesterol levels), and therefore these individuals should have a moderate fat restriction.
- Alzheimer’s Disease Risk:
The APOE e2 allele may provide some protection against Alzheimer’s disease; while the e3 allele is believed to play a neutral role in the development of the disease.
However, this does not necessarily mean that you won’t develop Alzheimer’s disease in the future.
APOE e2/e4
APOE e2/e4 genotype is the least common. People with this genotype have neither an increased or decreased risk of developing cardiovascular disease (strokes, heart attacks).
- Alzheimer’s Disease Risk:
The APOE e4 allele is associated with an increased risk for Alzheimer’s disease (AD), particularly of late-onset (AD that develops after the age of 65). Having just one e4 allele means that your risk of developing late-onset AD is approximately two to three times greater than it is for people who don’t have the allele.
However, this allele alone is neither sufficient nor necessary for the development of the disease.
APOE e3/e3
APOE e3/e3 genotype is the most common. People with this genotype have neither an increased or decreased risk of developing cardiovascular disease (strokes, heart attacks).
- Alzheimer’s Disease Risk:
People with the APOE e3/e3 genotype have neither an increased or decreased risk of developing Alzheimer’s disease.
APOE e3/e4
The e3/e4 APOE genotype is associated with increased triglycerides and total cholesterol levels in the blood, which leads to a high risk for cardiovascular disease (strokes, heart attacks).
These individuals respond poorly to treatment with a class of lipid-lowering drugs called statins; however, they respond well to extremely low-fat diets.
- Alzheimer’s Disease Risk:
The APOE e4 allele is associated with an increased risk for Alzheimer’s disease (AD), particularly of late-onset (AD that develops after the age of 65). Having just one e4 allele means that your risk of developing late-onset AD is approximately two to three times greater than it is for people who don’t have the allele.
However, this allele alone is neither sufficient nor necessary for the development of the disease.
APOE e4/e4
The e4/e4 APOE genotype is associated with increased triglycerides and total cholesterol levels in the blood, which leads to a high risk for cardiovascular disease (strokes, heart attacks).
These individuals respond poorly to treatment with a class of lipid-lowering drugs called statins; however, they respond well to extremely low-fat diets.
- Alzheimer’s Disease Risk:
The APOE e4 allele is associated with an increased risk for Alzheimer’s disease (AD), particularly of late-onset (AD that develops after the age of 65). Having two e4 alleles means that your risk of developing late-onset AD is approximately ten to fifteen times greater than it is for people who don’t have the allele.
However, this allele alone is neither sufficient nor necessary for the development of the disease.